International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-5 doi: 10.5281/zenodo.10169624
Original Article
A Retrospective Study of Comparison between Conservative and Operative Management in A Liver Trauma Patient at A Tertiary Healthcare Center
 ,
 ,
 ,
Published
Oct. 30, 2023
Abstract

Introduction: The liver is one of the most frequently damaged organs and remains the most common cause of death following blunt abdominal trauma. Currently, a conservative management constitutes the treatment of choice in patients with hemodynamic stability..

Aim and Objective: We aimed to analyze the effectiveness and morbi-mortality of both conservative and surgical treatment options.

Material and Methods: This prospective study was conducted at the Dept. of Traumatology and Surgery, MGM Hospital, Jaipur, Rajasthan, from April 2023 to July 2023. The study used non-probability consecutive sampling to select 80 liver trauma patients. The patients included were at least 18 years old and of both genders, and they were trauma patients who were hemodynamically stable at the time of presentation and voluntarily agreed to participate in the study.

Results: The study included patients with a mean age of 40.32 ± 11.5 years. The most prevalent types of extra-abdominal injuries among the patients were pancreas injuries (17.5%), CNS (Central Nervous System) injuries (57.5%), chest injuries (15%), diaphragm injuries (15%), spleen injuries (16.2%), and kidney injuries (10%). There was a significant variation (p=0.000) observed in the ICU stay and hospital stay between both study groups. We found 3.3% mortality in conservative group and 25% in operative group.

Conclusion: Conservative treatment is an adequate treatment in mild to moderate liver injury patients. Failure of conservative treatment did not show a higher incidence of complications or mortality but it should be performed in centres with experienced surgeons.

Recommended Articles
Loading Image...
Volume-4, Issue-5
Citations
224 Views
414 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved